Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

ClinicalTrials.gov ID: NCT00761631

Public ClinicalTrials.gov record NCT00761631. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 7:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Open Label Trial Evaluating the Safety,Tolerability and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Healthy Children Aged 15 Months to 17 Years in the United States

Study identification

NCT ID
NCT00761631
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
1,200 participants

Conditions and interventions

Interventions

  • 13 valent pneumococcal conjugate vaccine Biological

Biological

Eligibility (public fields only)

Age range
15 Months to 17 Years
Sex
All
Healthy volunteers
Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 30, 2008
Primary completion
Jun 30, 2010
Completion
Jun 30, 2010
Last update posted
Jul 30, 2013

2008 – 2010

United States locations

U.S. sites
31
U.S. states
21
U.S. cities
31
Facility City State ZIP Site status
Pfizer Investigational Site Benton Arkansas 72019
Pfizer Investigational Site Fayetteville Arkansas 72703
Pfizer Investigational Site Jonesboro Arkansas 72401
Pfizer Investigational Site Little Rock Arkansas 72205
Pfizer Investigational Site Fountain Valley California 92708
Pfizer Investigational Site Loma Linda California 92354
Pfizer Investigational Site Torrance California 90502
Pfizer Investigational Site Tampa Florida 33606
Pfizer Investigational Site Marietta Georgia 30062
Pfizer Investigational Site DeKalb Illinois 60115
Pfizer Investigational Site Louisville Kentucky 40202-3830
Pfizer Investigational Site Saint Paul Minnesota 55108
Pfizer Investigational Site Lebanon New Hampshire 03756
Pfizer Investigational Site Whitehouse Station New Jersey 08809
Pfizer Investigational Site Rochester New York 14618
Pfizer Investigational Site Cary North Carolina 27518
Pfizer Investigational Site Bismarck North Dakota 58501
Pfizer Investigational Site Fargo North Dakota 58103
Pfizer Investigational Site Cincinnati Ohio 45229
Pfizer Investigational Site Cleveland Ohio 44121
Pfizer Investigational Site Tulsa Oklahoma 74127
Pfizer Investigational Site Philadelphia Pennsylvania 19107
Pfizer Investigational Site Clarksville Tennessee 37043
Pfizer Investigational Site Galveston Texas 77555-0351
Pfizer Investigational Site San Antonio Texas 78229
Pfizer Investigational Site Murray Utah 84107
Pfizer Investigational Site Salt Lake City Utah 84132
Pfizer Investigational Site South Jordan Utah 84095
Pfizer Investigational Site Vienna Virginia 22180
Pfizer Investigational Site Vancouver Washington 98664
Pfizer Investigational Site Monroe Wisconsin 53566

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00761631, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 30, 2013 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00761631 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →